text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 117772-70-0 | Product Number: A2076

Azithromycin Dihydrate


Purity: >98.0%(N)
Synonyms:
Product Documents:
1G
55,00 €
12   ≥100 
5G
183,00 €
3   ≥100 

*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).


Product Number A2076
Purity / Analysis Method >98.0%(N)
Molecular Formula / Molecular Weight C__3__8H__7__2N__2O__1__2·2H__2O = 785.03 
Physical State (20 deg.C) Solid
Storage Temperature Room Temperature (Recommended in a cool and dark place, <15°C)
Packaging and Container 1G-Glass Bottle with Plastic Insert (View image)
CAS RN 117772-70-0
Related CAS RN 83905-01-5
Reaxys Registry Number 4776338
PubChem Substance ID 87560212
SDBS (AIST Spectral DB) 52117
Merck Index (14) 915
MDL Number

MFCD01862248

Specifications
Appearance White powder to crystal
Purity(with Total Nitrogen) min. 98.0 %
Specific rotation [a]20/D -45.0 to -49.0 deg(C=2, EtOH)(calcd.on anh.substance)
Water 4.0 to 5.0 %
Properties (reference)
Specific Rotation -47° (C=2,EtOH)
Solubility (soluble in) Methanol
GHS
Related Laws:
Transport Information:
HS Number 2941900000
Application
Azithromycin: A More Acid-Stable Semi-Synthetic Macrolide Antibiotic

Macrolide antibiotics are classified by the size of the macrocyclic lactone ring of aglycone as 14-, 15- or 16-membered ring macrolides. Macrolides are characterized by similar chemical structures, mechanisms of action and resistance, but vary in the different pharmacokinetic parameters, and spectrum of activity. Azithromycin (abbrev: AZM), the first azalide macrolide, is chemically synthesized from erythromycin [E0751], with a methyl-substituted nitrogen atom incorporated into the acid-stable lactone ring, thus making the 15-membered lactone ring. AZM is marginally less active than erythromycin in vitro against Gram-positive organisms, but is more active than erythromycin and clarithromycin [C2220] against many Gram-negative pathogens including Haemophilus influenzae and Neisseria gonorrhoeae, and Mycoplasma pneumoniae. However, erythromycin-resistant organisms are also resistant to AZM. AZM is subsequently slowly released, reflecting its long terminal phase elimination half-life relative to that of erythromycin. AZM inhibits protein synthesis in susceptible organisms by binding to specific nucleotides in 23S rRNA within the 50S subunit of the bacterial ribosome.

References


PubMed Literature


TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The product with the lot number searched for has been discontinued and no related documentation is available.

Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.

A sample C of A for this product is not available at this time.

Analytical Charts
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The requested analytical chart is not available. Sorry for the inconvenience.

The product with the lot number searched for has been discontinued and no related documentation is available.

Other Documents

Session Status
Your session will timeout in 10 minutes. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page. minute. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page.

Your session has timed out. You will be redirected to the HOME page.